Changchun Bcht Biotechnology Co. — Investor Relations & Filings
Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 长春百克生物科技股份公司2025年年度股东会决议公告 | 2026-05-15 | Chinese | |
| 长春百克生物科技股份公司2025年度独立董事述职报告（凌虹） | 2026-04-21 | Chinese | |
| 长春百克生物科技股份公司董事、高级管理人员薪酬管理制度 | 2026-04-21 | Chinese | |
| 长春百克生物科技股份公司2025年环境、社会和公司治理报告摘要 | 2026-04-21 | Chinese | |
| 长春百克生物科技股份公司关于2025年度募集资金存放、管理与实际使用情况的专项报告 | 2026-04-21 | Chinese | |
| 长春百克生物科技股份公司关于召开2025年年度股东会的通知 | 2026-04-21 | Chinese |
Browse filings by year
6 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 46364375 | 长春百克生物科技股份公司2025年年度股东会决议公告 | 2026-05-15 | Chinese | ||
| 44572138 | 长春百克生物科技股份公司2025年度独立董事述职报告（凌虹） | 2026-04-21 | Chinese | ||
| 44572119 | 长春百克生物科技股份公司董事、高级管理人员薪酬管理制度 | 2026-04-21 | Chinese | ||
| 44572113 | 长春百克生物科技股份公司2025年环境、社会和公司治理报告摘要 | 2026-04-21 | Chinese | ||
| 44572106 | 长春百克生物科技股份公司关于2025年度募集资金存放、管理与实际使用情况的专项报告 | 2026-04-21 | Chinese | ||
| 44572097 | 长春百克生物科技股份公司关于召开2025年年度股东会的通知 | 2026-04-21 | Chinese | ||
| 44572085 | 长春百克生物科技股份公司内部审计管理制度 | 2026-04-21 | Chinese | ||
| 44572076 | 长春百克生物科技股份公司第六届董事会第十二次会议决议的公告 | 2026-04-21 | Chinese | ||
| 44572059 | 长春百克生物科技股份公司2025年度独立董事述职报告（吴安平） | 2026-04-21 | Chinese | ||
| 44572040 | 长春百克生物科技股份公司董事会审计委员会2025年度履职情况报告 | 2026-04-21 | Chinese | ||
| 44572015 | 长春百克生物科技股份公司2026年第一季度报告 | 2026-04-21 | Chinese | ||
| 44572012 | 长春百克生物科技股份公司2025年度独立董事述职报告（施维） | 2026-04-21 | Chinese | ||
| 44571997 | 长春百克生物科技股份公司关于续聘2026年度财务审计机构及内控审计机构的公告 | 2026-04-21 | Chinese | ||
| 44571995 | 长春百克生物科技股份公司2025年度”提质增效重回报“行动方案的年度评估报告暨2026年度”提质增效重回报“行动方案 | 2026-04-21 | Chinese | ||
| 44571992 | 长春百克生物科技股份公司内部控制审计报告 | 2026-04-21 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Changchun Bcht Biotechnology Co. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58294/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58294 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58294 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58294 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58294}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Changchun Bcht Biotechnology Co. (id: 58294)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.